Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Pick the Best Material Organization: Insider Tips - 2Air New Zealand cuts flights and hikes fares as fuel prices surge
- 3Dave Coulier reveals he has tongue cancer, his 2nd diagnosis in a year, after beating non-Hodgkin lymphoma
- 4Red Crescent: More than 100,000 civilian structures damaged in Iran
- 5November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- Telescope in Chile captures stunning new picture of a cosmic butterfly
- Volkswagen Just Revealed a Massive Range-Extended SUV for China, and America Isn’t Getting It
- IDF destroys Hamas shaft in northern Gaza with loaded 'ready to fire' rocket aimed at Sderot
- The Way to Recuperation: Defeating Dependence
- What is the Significant Tech Expertise to Master Today?
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Moon milestones: A rundown of Artemis 2's many spaceflight firsts
- Nordic people know how to beat the winter blues. Here's how to find light in the darkest months
